Where does Chimera Bioengineering, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Chimera Bioengineering, Inc. ranks #13,916 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Chimera Bioengineering, Inc. hold?

Chimera Bioengineering, Inc. holds 21 US utility patents granted between 2017 and 2023, spanning 8 technology areas.

What is Chimera Bioengineering, Inc.'s Innovation Score?

Chimera Bioengineering, Inc. has an Innovation Score of 34.6 out of 100 (48th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Chimera Bioengineering, Inc.'s patent grant rate increasing or decreasing?

Chimera Bioengineering, Inc.'s recent grant velocity is +150% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Chimera Bioengineering, Inc.'s patents?

Chimera Bioengineering, Inc.'s patents average 15.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Chimera Bioengineering, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Chimera Bioengineering, Inc.

Q: What technology areas does Chimera Bioengineering, Inc. focus on?

Chimera Bioengineering, Inc.'s top technology area is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media) with 21 patents, ranking #514 of 4,144 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

USPTO PatentsView assignee record - 21 granted patents across 8 technology areas, recorded in grant years 2017–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Chimera ranks #13,916 of 49,997 tracked US assignees by granted-patent volume, with 21 patents across 8 technology areas.

#13,916
of 49,997 US assignees by volume: 48th percentile
by Innovation Score (34.6/100): 15.8
avg claims per patent: +150%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R13916 · US Corporation #13,916 · 21 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 21 grants
MID-PACK #13,916/49,997
PHOTO-FINISH Cascade Microtech
CPC-NARROW C12N · 8 areas
INNOV-THIN 34.6/100
CLAIMS-RICH 15.8 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +150% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Cascade Microtech, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Chimera’s 34.6 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.7 pts (31%) Velocity 4.4 pts (13%) Breadth 10.0 pts (29%) Claim depth 9.5 pts (27%)

Qualcomm Incorporated · highest

85
Chimera Bioengineering · this assignee

35
3D Lighting… · lowest

7

What this shows Chimera's Innovation Score is 34.6/100 (48th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Chimera?

Each dot is one of Chimera’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Chimera’s own 15.8 claims/patent is at or below the 18.1 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Chimera vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Chimera's grants concentrate

Chimera Bioengineering, Inc. is a focused PatentsView assignee: 8 CPC subclasses with 100% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2019 (5 grants) versus a trough of 1 in 2017. By volume, Chimera sits between Cascade Microtech, Inc. and Clearvue Technologies Ltd.

Chimera's three-year grant acceleration

Chimera Bioengineering, Inc. shows 8 grants in 2022–2024 against only 12 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Cascade Microtech

21
Cavitation

21
Champion Microele…

21
Chengdu Haicun IP…

21
Ciari Guitars

21
Cisco

21
Classiq

21
Clearvue

21
Chimera Bioengine… ◀

21

What this shows Chimera holds 21 patents at rank #13,925, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Chimera

By rank, the assignees closest to #13,925 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Chimera's primary technology class.

Chimera's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

35 48th percentile higher than 48% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Chimera Bioengineering, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	1	4.8%
2019	5	23.8%
2020	4	19.0%
2021	3	14.3%
2022	5	23.8%
2023	3	14.3%

Which technologies does Chimera Bioengineering, Inc. patent most?

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 21

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 17

C07K - Peptides 13

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 13

C12Y - Enzymes 8

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 8

C40B - Combinatorial CHEMISTRY; Libraries, e.g. Chemical Libraries 3

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 3

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Chimera Bioengineering, Inc.'s patent record in context - here's where to go next.

Chimera Bioengineering, Inc.'s lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 100% of its portfolio - see every assignee active in that class. Explore C12N
Ranked #13,916 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Chimera Bioengineering, Inc. against Cascade Microtech, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 34.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.